Why AngioDynamics Stock Got Destroyed Today
Investors in AngioDynamics (NASDAQ: ANGO), inventor of the innovative Nanoknife device for electrocuting cancer cells, got an unpleasant shock of their own on Friday morning. Though the company reported a smaller adjusted loss than had been forecast for its fiscal 2024 second quarter, it also reported smaller than expected revenues, and offered worse guidance for the rest of its fiscal year.
As of 3 p.m. ET, AngioDynamics shares were down by 21.1%.
For the period, which ended Nov. 30, AngioDynamics' sales grew by less than 3% year over year to $79.1 million, missing Wall Street's consensus estimate of $82 million. The company also suffered a small decline in gross profit margins, from 51.7% in the prior-year period to 50.9%.
Source Fool.com
Angiodynamics Inc. Stock
€12.70
0.790%
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Angiodynamics Inc. stock is not clear.
With a target price of 13 € there is a slightly positive potential of 2.36% for Angiodynamics Inc. compared to the current price of 12.7 €.
